CA19-9 (121SLE), MMab

Description

CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. It was discovered in patients with Colon Cancer and Pancreatic Cancer in 1981. Increased levels of CA 19-9 are also found in non-malignant conditions, such as Mirizzi’s Syndrome and diseases of the bile duct and liver. The main use of CA19-9 antibody is to determine whether a pancreatic tumor is secreting it; if that is the case, then the levels should fall when the tumor is treated, and they may rise again if the disease recurs. CA19-9 antigen is highly expressed in Gastrointestinal (gastric, pancreatic, and colonic) Adenocarcinomas and salivary gland Mucoepidermoid Carcinomas. CA19-9 antibody is usually not reactive with breast, kidney, and prostate Carcinomas, but is reactive with sialylated Lea-active pentasaccharide (sialylated lacto-N-fucopentaose II), which is enzymatically synthesized by sialylation of Type 1 carbohydrate chains.

Caractéristiques

Type

Mouse Monoclonal

Clone

121SLE

Isotype

IgM

Réactivité

Paraffin, Frozen

Localisation

Cytoplasmic

Contrôle

Breast, Colon, Cervix, Pancreas, Pancreas Cancer, Breast Carcinoma, Colon Carcinoma, Transitional Cell Carcinoma, Ovarian Carcinoma Thyroid Carcinoma

Usage prévu

For In Vitro Diagnostic Use